Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Expansion Is Reshaping Competitive Dynamics Across The Industry
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Growth Potential: How Will Market Size Change Through 2030?
The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market size has experienced rapid expansion in recent years. This market is anticipated to increase from $39.69 billion in 2025 to $45.88 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.6%. The historical growth of this market can be attributed to covid 19 vaccine breakthroughs, prior viral vector research, global pandemic preparedness programs, advances in genomic sequencing, and early nucleic acid vaccine trials.
The messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market is projected to experience significant expansion in the coming years. It is forecast to reach $82.61 billion by 2030, driven by a compound annual growth rate (CAGR) of 15.8%. This growth during the forecast period can be attributed to several factors, including the increasing development of personalized cancer vaccines, the broadening of infectious disease pipelines, more rapid platform-based approvals, a surge in biotech funding, and the wider adoption of therapeutic vaccines. Furthermore, prominent trends anticipated during this period encompass self-amplifying mRNA platforms, optimized lipid nanoparticle delivery, modular vaccine platform design, swift adaptation to pathogen targets, and the emergence of next-generation adjuvant systems.
Download A Free Sample Report For Comprehensive Market Insights:
Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Growth Momentum: Which Factors Are Influencing Demand?
The rising need for individualized healthcare approaches is anticipated to drive expansion within the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market in the future. This medical strategy, personalized medicine, involves customizing disease prevention and treatment plans according to a person’s unique genetic makeup, molecular traits, and particular health status. The heightened requirement for personalized medicine stems from the increasing occurrence of intricate and long-term illnesses, given that such conditions necessitate precise, patient-focused therapeutic interventions to enhance the effectiveness and safety of treatments. Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms facilitate personalized medicine by allowing for the quick, adaptable, and very specific creation of vaccines and therapies, which can be adapted to an individual’s genetic and disease characteristics, thereby promoting precise healthcare provision. An example illustrates this: in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that the FDA approved 16 novel personalized treatments for patients with rare diseases in 2023, a notable increase from six in 2022. Consequently, the escalating need for personalized medicine is fostering the expansion of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market.
Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Segment Analysis: What Are The Major Market Categories?
The messenger ribonucleic acid (mrna) and next-generation vaccine platforms market covered in this report is segmented –
1) By Vaccine Type: Messenger Ribonucleic Acid Vaccines; Deoxyribonucleic Acid (DNA) Vaccines; Viral Vector Vaccines; Protein Subunit Vaccines; Peptide Vaccines; Other Vaccine Types
2) By Technology or Platform: Lipid Nanoparticle (LNP) Delivery; Self-Amplifying Messenger Ribonucleic Acid; Circular Messenger Ribonucleic Acid; Replicon or Non-replicating Platforms; Viral Vector Technologies
3) By Disease Indication: Infectious Diseases; Oncology; Rare Diseases; Other Disease Indications
4) By End User: Pharmaceutical and Biotechnology Companies; Contract Research Organizations (CROs); Academic and Research Institutes; Hospitals and Clinics
Subsegments:
1) By Messenger Ribonucleic Acid Vaccines: Conventional Messenger Ribonucleic Acid Vaccines; Self Amplifying Messenger Ribonucleic Acid Vaccines; Modified Messenger Ribonucleic Acid Vaccines; Circular Messenger Ribonucleic Acid Vaccines
2) By Deoxyribonucleic Acid Vaccines: Plasmid Deoxyribonucleic Acid Vaccines; Viral Assisted Deoxyribonucleic Acid Vaccines; Synthetic Deoxyribonucleic Acid Vaccines; Gene Based Deoxyribonucleic Acid Vaccines
3) By Viral Vector Vaccines: Adenovirus Based Viral Vector Vaccines; Lentivirus Based Viral Vector Vaccines; Poxvirus Based Viral Vector Vaccines; Measles Virus Based Viral Vector Vaccines
4) By Protein Subunit Vaccines: Recombinant Protein Vaccines; Virus Like Particle Vaccines; Toxoid Based Protein Vaccines; Polysaccharide Conjugate Vaccines
5) By Peptide Vaccines: Synthetic Peptide Vaccines; Personalized Peptide Vaccines; Multi Epitope Peptide Vaccines; Long Peptide Vaccines
6) By Other Vaccine Types: Protein Subunit Vaccines, Virus-Like Particle Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vector Vaccines
Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Trends Reshaping Industry Growth
Leading companies in the mRNA and next-generation vaccine platforms market are concentrating on the development of advanced mRNA-based COVID-19 vaccines to strengthen immune response duration, broaden coverage against variants, and elevate overall vaccine efficacy. These next-generation mRNA-based COVID-19 vaccines employ refined mRNA engineering and delivery techniques to offer more extensive and sustained protection against both existing and emerging SARS-CoV-2 variants. They also aim to improve safety, stability, and storage convenience, while facilitating rapid adaptation to viral evolution. For example, in June 2025, Moderna Inc., a US-based biotechnology company, launched mNEXSPIKE, its next-generation COVID-19 vaccine specifically crafted to enhance protection against circulating and emerging SARS-CoV-2 variants. This vaccine integrates an updated spike protein antigen that more closely corresponds to recent variants, seeking to provide improved immune durability and effectiveness, thereby supporting ongoing COVID-19 prevention strategies and future booster programs.
Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Leading Companies Driving Competitive Growth
Major companies operating in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Moderna Inc., BioNTech SE, Novavax Inc., Walvax Biotechnology Co Ltd, Arcturus Therapeutics Inc, Gennova Biopharmaceuticals Ltd, Vaxxas Pty Ltd, Vaxart Inc, Ethris GmbH, The Biologicals and Vaccines Institute of Southern Africa Proprietary Limited, eTheRNA Immunotherapies NV, Stemirna Therapeutics Co Ltd, Primrose Bio Inc, Acuitas Therapeutics Inc, and Incepta Vaccine Ltd.
Access The Complete Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Report:
#Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
